Dr. Lior Shaltiel reports

NUREXONE ADVANCES U.S. GROWTH STRATEGY WITH ACCEPTANCE INTO PRESTIGIOUS ARMI HEALTHTECH HUB ACCELERATOR AND PROVIDES CORPORATE UPDATE

Nurexone Biologic Inc. has been accepted into the HealthTech Hub (HTH) accelerator program. Based in Boston, Mass., home to more than 1,000 biotech companies, HTH is operated by the Advanced Regenerative Manufacturing Institute (ARMI) and its BioFabUSA initiative.

Nurexone's acceptance into the prestigious HTH accelerator program will support the company's expansion into the U.S. market following the establishment of Exo-Top Inc., the company's wholly owned U.S. subsidiary dedicated to GMP-compliant (good manufacturing practices) exosome manufacturing for clinical development and commercial scale-up.

HTH, co-led by ARMI and Mass General Brigham, is a competitive accelerator program supported by the U.S. Department of Health and Human Services and Israel's Ministry of Health. The HTH accelerator program selects a limited number of innovative companies each year to help them validate U.S. clinical relevance, strengthen commercialization strategies and build meaningful collaborations with key stakeholders across the U.S. health technology landscape. The program is funded by HTH at no cost to participants.

Dr. Lior Shaltiel, chief executive officer of Nurexone, commented: "The HTH acceleration program offers the kind of U.S.-based insight and guidance needed at this stage of our growth. As we establish Exo-Top to manufacture clinical-grade exosomes in the U.S., the HTH will help us sharpen our regulatory and scale-up strategies and pursue meaningful commercial collaboration opportunities. This is a timely and strategic opportunity to accelerate our commercialization pathway in the world's largest health care market."

Nurexone's participation in the HTH accelerator program is expected to enhance its visibility within the U.S. regenerative medicine ecosystem and to support its mission to bring novel exosome-based therapeutics to patients with unmet needs.

Omnibus plan approval

The company is pleased to announce that, further to its press release dated June 4, 2025, at the company's annual general and special meeting held on June 18, 2025, disinterested shareholders ratified and approved the amended and restated omnibus incentive plan, a copy of which is available under the company's SEDAR+ profile.

The omnibus plan is a hybrid plan that provides flexibility to grant equity incentive awards in the form of stock options, restricted shares and restricted share units (RSUs).

The omnibus plan is a hybrid 10-per-cent rolling and 10-per-cent fixed share-based compensation plan that amends and restates the company's previous equity incentive plan approved by shareholders on June 4, 2024. The previous plan was a 20-per-cent fixed share-based compensation plan, whereby the maximum number of common shares in the capital of the company reserved for issuance was set at 13,166,085, representing 20 per cent of the issued and outstanding common shares as of the effective date.

The omnibus plan now includes: (i) a 10-per-cent rolling option component that shall not exceed 10 per cent of the company's total issued and outstanding common shares from time to time; and (ii) a 10-per-cent fixed component permitting up to 7,800,781 RSUs and restricted shares in the aggregate.

Additionally, the omnibus plan was amended to increase the number of securities issuable to insiders of the company. The previous plan provided that, unless approved by disinterested shareholders: (i) the maximum number of securities issuable to insiders collectively would not exceed 10 per cent of the company's securities at any time; and (ii) the maximum number of securities issuable to insiders collectively in any 12-month period would not exceed 10 per cent of the company's total issued and outstanding securities as at the date any award was granted to an insider. Now, the omnibus plan provides that: (i) the maximum number of the company's securities issuable to insiders collectively shall not exceed 20 per cent of the company's total issued and outstanding common shares at any point in time; and (ii) the maximum number of the company's securities issuable to insiders collectively, in any 12-month period, when combined with all of the company's other share compensation arrangements, shall not exceed 20 per cent of the company's total issued and outstanding securities, calculated as at the date any award is granted or issued to any insider.

RSU grants

In addition, the company announced that it has granted an aggregate of 1,125,000 RSUs to certain officers and directors of the company pursuant to the terms and conditions of the omnibus plan. Each RSU vests on the one-year anniversary of the grant date and may be settled, upon their vesting, into one common share. The RSUs and underlying common shares are subject to the exchange hold period (as such term is defined under the policies of the TSX Venture Exchange).

About Nurexone Biologic Inc.

Nurexone Biologic is a TSX-V-, OTCQB- and Frankfurt-listed biotechnology company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multibillion-dollar markets. Regulatory milestones, including obtaining the orphan drug designation, facilitate the road map toward clinical trials in the United States and Europe. Commercially, the company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. Nurexone has established Exo-Top, a U.S. subsidiary, to anchor its North American activity and growth strategy.

We seek Safe Harbor.